文献速递药物相互作用药物不良反应与药物警戒抗栓抗凝管理

口服抗凝药相互作用药物胃肠道出血风险预测模型

A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications.
PubMed 文献 · Pharmacotherapy · 2026-01-01

本研究开发并验证了DIOAC-GIB模型,用于预测口服抗凝药患者因相互作用药物等因素导致的胃肠道出血风险。模型基于关键试验的出血率及Meta分析或文献获得的各风险因素比值比构建,并与HAS-BLED和DOAC评分进行相关性比较,两者相关系数均为0.5(p<0.01)。该模型有助于识别高风险患者并辅助制定个体化治疗方案。

要点

  • DIOAC-GIB模型整合了NSAIDs、SSRI/SNRI、抗血小板药、PPI等药物相互作用及年龄、出血史等因素。
  • NSAIDs中酮咯酸的GIB风险OR最高达20.67,塞来昔布最低为1.16。
  • PPI可降低GIB风险(OR=0.67),而既往GIB史(OR=5.14)和年龄>65岁(RR=2.50)显著增加风险。

核心结论

  • DIOAC-GIB是一种新型GIB风险模型,纳入口服抗凝药的药效学相互作用,可辅助临床决策。
  • 该模型与HAS-BLED和DOAC评分的相关系数均为0.5(p<0.01),可能有助于识别高风险患者。

研究设计与样本

  • 开发并验证GIB风险预测模型DIOAC-GIB,输入参数来自随机效应Meta分析或文献。
  • 模型基于关键试验的GIB发生率:阿哌沙班1.16%、利伐沙班3.15%、达比加群3.00%、依度沙班3.31%、华法林2.00%。

主要发现

  • NSAIDs的GIB比值比范围从塞来昔布1.16(95%CI 0.84-1.61)到酮咯酸20.67(95%CI 14.56-29.34)。
  • SSRI/SNRIs的GIB比值比范围从帕罗西汀1.31(95%CI 1.07-1.62)到文拉法辛1.50(95%CI 1.32-1.70)。
  • 年龄>65岁相对风险2.50(95%CI 1.2-5.5),GIB史OR=5.14(95%CI 3.92-6.73)。
  • 阿司匹林OR=1.31(95%CI 0.93-1.85),抗血小板药OR=1.97(95%CI 1.73-2.25),糖皮质激素OR=1.69(95%CI 1.53-1.87)。
  • PPI降低GIB风险OR=0.67(95%CI 0.62-0.74)。

关键数值与推荐

  • GIB风险预测纳入因素:NSAIDs、SSRI/SNRIs、阿司匹林、抗血小板药、PPI、年龄、GIB史。
  • 模型与HAS-BLED和DOAC评分的相关系数均为0.5(p<0.01)。

临床怎么用

  • 临床可借助DIOAC-GIB评估口服抗凝药患者的GIB风险,尤其关注合并相互作用药物及高危因素者。
  • 对于高风险患者,可考虑调整处方(如加用PPI或避免高风险NSAIDs)以降低出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pharmacodynamic drug-drug interactions (DDI) in patients receiving oral anticoagulants (OAC) may increase the risk of gastrointestinal bleeding (GIB). The purpose of this study was to develop and validate a GIB model for patients receiving OACs. METHODS: A risk model, Drug Interactions in Oral AntiCoagulants for Risk of Gastrointestinal Bleeding (DIOAC-GIB), was developed to predict GIB based on interacting medications and other patient-specific risk factors for patients on OAC. Inputs for the model were obtained using random-effect meta-analysis or from the literature for the following attributes: exposure to nonsteroidal anti-inflammatory drugs (NSAIDs); selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (SSRI/SNRIs); aspirin, antiplatelet medications, and proton pump inhibitors (PPIs); age; and GIB history. The model was correlated to existing OAC models (HAS-BLED and DOAC score). RESULTS: GIB risk for OACs was based on pivotal trials (1.16% for apixaban; 3.15% for rivaroxaban; 3.00% for dabigatran; 3.31% for edoxaban; and 2.00% for warfarin). The odds ratio (OR) of GIB for NSAIDs ranged from 1.16 (95% confidence interval [CI]: 0.84-1.61) for celecoxib to 20.67 (95% CI: 14.56-29.34) for ketorolac. ORs for GIB among SSRI/SNRIs ranged from 1.31 (95% CI: 1.07-1.62) for paroxetine to 1.50 (95% CI: 1.32-1.70) for venlafaxine. Risk of GIB also included persons > 65 years of age (relative risk = 2.50, 95% CI: 1.2-5.5); history of GIB (OR = 5.14, 95% CI: 3.92-6.73); exposure to aspirin (OR = 1.31, 95% CI: 0.93-1.85), antiplatelet medications (OR = 1.97, 95% CI: 1.73-2.25), and corticosteroids (OR = 1.69, 95% CI: 1.53-1.87); and PPIs reduced GIB risk (OR = 0.67, 95% CI: 0.62-0.74). Correlations between the DIOAC-GIB and HAS-BLED and DOAC scores were 0.5 for both (p < 0.01). CONCLUSION: DIOAC-GIB is a novel GIB-risk model that incorporates pharmacodynamic OAC DDIs to assist clinicians and patients to determine a therapeutic plan while accounting for GIB risk. DIOAC-GIB correlates with other bleeding risk scores and may help identify high-risk patients who may benefit from tailored prescribing.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Gomez-Lumbreras A, Tawfik AG, Reese T, et al. A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications. Pharmacotherapy. 2026. PMID: 42927649. doi:10.1002/phar.70205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。